Metrics as of 10/16/2026, 07:45 PM (Berlin time), refresh in progress.
Coherus Oncology Stock
Coherus Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dennis Lanfear
- Employees
- 144
- Market cap
- $155 M
- IPO
- 06/11/2014
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony…
Coherus Oncology stock: price history
1D
-6.1%
1W
-6.1%
1M
-17.6%
6M
-49.2%
YTD
-29.2%
1Y
-41.2%
2Y
+13.4%
5Y
-94.1%
10Y
-96.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~56% stronger price swings than usual
Ask the agents about Coherus Oncology
Analyst assessment of Coherus Oncology
PRICE TARGET LOW
US$1.05
CONSENSUS
US$6.02
MEDIAN
US$6.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
14
BUY
3
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 07/08/2026
Coherus Oncology stock metrics
P/E
-0.99
P/B
2.56
EV/EBITDA
-0.74
RETURN ON EQUITY
-33.9%
NET MARGIN
-144.2%
DEBT/EQUITY
0.62
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.8%
FLOAT SHARES
135,602,408
AVG. DAILY VOLUME (30D)
1,484,182
Insider transactions (SEC)
Newton Charles W.
Wahlstrom Mats
O'Donnell-Tormey Jill
Ryan Michael Lee
Newcomer Lee Nisley
Institutional holders
Comparable stocks
Frequently asked questions about Coherus Oncology stock
What does Coherus Oncology do?
Coherus Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dennis Lanfear, the company employs around 144 people.
The IPO was on 06/11/2014; the stock trades on NASDAQ under the ticker CHRS.
What do analysts say about Coherus Oncology stock?
17 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$6.02, ranging from US$1.05 to US$11.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Coherus Oncology report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Coherus Oncology pay a dividend?
No, Coherus Oncology currently does not pay a dividend.
Which stocks are comparable to Coherus Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Coherus Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Coherus Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.